NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $7.27 +0.68 (+10.32%) Closing price 04:00 PM EasternExtended Trading$7.26 0.00 (-0.07%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Capricor Therapeutics Stock (NASDAQ:CAPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$6.64▼$7.3350-Day Range$3.85▼$10.0652-Week Range$2.96▼$40.37Volume3.35 million shsAverage Volume3.13 million shsMarket Capitalization$422.68 millionP/E RatioN/ADividend YieldN/APrice Target$30.25Consensus RatingHold Company Overview Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research is based on technologies intended to modulate inflammation, fibrosis and tissue damage, with an emphasis on rare and degenerative conditions. Capricor’s lead investigational product is deramiocel, formerly known as CAP-1002. It is an allogeneic cell therapy derived from cardiosphere-derived cells and is being developed for Duchenne muscular dystrophy, a progressive genetic disorder that causes muscle degeneration. The company has also developed an exosome technology platform for potential use in vaccines, therapeutics and drug delivery. Founded in 2005 and headquartered in Beverly Hills, California, Capricor conducts its development activities primarily in the United States and works with research and industry partners as its programs advance. The company is led by Linda Marbán, Ph.D., who serves as president and chief executive officer and has been associated with the company since its formation.AI Generated. May Contain Errors. Read More Capricor Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCAPR MarketRank™: 3.074209563625 of 5 starsCapricor Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 453rd out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingCapricor Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialCapricor Therapeutics has a consensus price target of $30.25, representing about 316.1% upside from its current price of $7.27.Amount of Analyst CoverageCapricor Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.66% of the float of Capricor Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 4.52.Change versus previous monthShort interest in Capricor Therapeutics has recently decreased by 4.35%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentCapricor Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Capricor Therapeutics this week, compared to 9 articles on an average week.Search Interest33 people have searched for CAPR on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows12 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.20% of the stock of Capricor Therapeutics is held by insiders.Percentage Held by Institutions21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPR Stock News HeadlinesCapricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy TranscriptOctober 7, 2026 | seekingalpha.comCAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA DecisionOctober 7, 2026 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 15 at 1:00 AM | Porter & Company (Ad)Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Now Rated "Hold" by Wall Street AnalystsOctober 7, 2026 | americanbankingnews.comCapricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data On Deramiocel For Upper Limb Function In Duchenne Muscular DystrophyOctober 5, 2026 | marketscreener.comMCapricor's Deramiocel Slows Upper Limb Decline In Duchenne Muscular DystrophyOctober 5, 2026 | rttnews.comCapricor’s DMD therapy shows 76% slower upper-limb decline — this analyst expects a complete response letter in NovemberOctober 5, 2026 | msn.comCapricor drops as deramiocel OLE data fails to quell regulatory concernsOctober 5, 2026 | seekingalpha.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $28.86 at the start of the year. Since then, CAPR stock has decreased by 74.8% and is now trading at $7.27. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics, Inc. (NASDAQ:CAPR) posted its quarterly earnings results on Thursday, August, 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.11. Read the conference call transcript. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Micron Technology (MU), Vaxart (VXRT), Alibaba Group (BABA) and Salesforce (CRM). Company Calendar Last Earnings8/13/2026Today10/15/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CAPR's financial health is in the Green zone, according to TradeSmith. CAPR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CAPR CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075Employees231Year Founded2005Price Target and Rating Average Price Target for Capricor Therapeutics$30.25 High Price Target$60.00 Low Price Target$2.00 Potential Upside/Downside+316.1%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.60% Return on Assets-43.97% Debt Debt-to-Equity RatioN/A Current Ratio7.35 Quick Ratio7.35 Sales & Book Value Annual Sales$22.27 million Price / Sales18.98 Cash FlowN/A Price / Cash FlowN/A Book Value$5.53 per share Price / Book1.31Miscellaneous Outstanding Shares58,140,000Free Float52,790,000Market Cap$422.68 million OptionableOptionable Beta0.61 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CAPR) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPR Stock Alerts